ResultsIQ

ResultsIQ › Latest results › Symbiotec Pharmalab Limited

Symbiotec Pharmalab Limited Q2 FY27 results deck summary

NSE: SYMBIOTEC · BSE: 544889

Results deck of 5 Nov 2026, summarised by AI from the filing.

Q2 FY27 consolidated revenue ₹280 cr (+43%) and PAT ₹52 cr (+169%), with new business revenue to start in 6–12 months.

Key takeaways

  1. New business revenue Revenue from new businesses is to commence in the next 6–12 months, with ~₹1,000 crs or 60% of capex starting to generate revenue.
  2. Milestone revenue Milestone revenue of ₹53 crs from the US DCV licensing agreement was recognised in Q2 FY27, with the rest expected in upcoming quarters.
  3. API growth API revenue grew 11% Y-o-Y in H1 FY27 on healthy volume growth and a favourable product mix.

Original filing on BSE

Symbiotec Pharmalab Limited Q2 FY27 results

As filed: Revenue ₹280 cr, EBITDA ₹91.5 cr, PAT ₹51.7 cr, EBITDA margin 32.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹280 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹211 cr, EBITDA ₹59.2 cr, PAT ₹47.0 cr, EBITDA margin 28.1%. Not scored. No result for the same quarter last year. Share price after the results: +4.5% in 30 days (Nifty 500: −4.5%).

Past price moves after results do not indicate future moves. Not a recommendation.

Symbiotec Pharmalab Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.